Analyst Ratings For AtriCure (NASDAQ:ATRC)
Today, Canaccord Genuity raised its price target on AtriCure (NASDAQ:ATRC) to $26.00 per share.
Some recent analyst ratings include
- 2/27/2018-Needham & Company LLC Reiterated Rating of Buy.
- 12/10/2017-Piper Jaffray Companies Reiterated Rating of Buy.
- 7/30/2017-Stifel Nicolaus Reiterated Rating of Buy.
- 6/16/2017-Leerink Swann Reiterated Rating of Outperform.
- 3/20/2017-Northland Securities Reiterated Rating of Buy.
- 3/6/2017-BTIG Research was Downgraded by analysts at BTIG Research from a “Buy ” rating to a ” Neutral” rating.
Recent Insider Trading Activity For AtriCure (NASDAQ:ATRC)
AtriCure (NASDAQ:ATRC) has insider ownership of 11.90% and institutional ownership of 89.49%.
- On 2/15/2018 Justin J Noznesky, SVP, sold 4,000 with an average share price of $17.03 per share and the total transaction amounting to $68,120.00.
- On 11/30/2017 M. Andrew Wade, CFO, sold 2,000 with an average share price of $18.41 per share and the total transaction amounting to $36,820.00.
- On 11/8/2017 B Kristine Johnson, Director, bought 1,500 with an average share price of $18.36 per share and the total transaction amounting to $27,540.00.
- On 8/22/2017 Elizabeth D Krell, Director, sold 10,000 with an average share price of $22.40 per share and the total transaction amounting to $224,000.00.
- On 5/17/2017 Elizabeth D Krell, Director, sold 10,000 with an average share price of $21.44 per share and the total transaction amounting to $214,400.00.
- On 3/17/2017 Andrew L Lux, SVP, sold 20,000 with an average share price of $18.85 per share and the total transaction amounting to $377,000.00.
- On 11/15/2016 Elizabeth D Krell, Director, sold 10,000 with an average share price of $19.73 per share and the total transaction amounting to $197,300.00.
Recent Trading Activity for AtriCure (NASDAQ:ATRC)
Shares of AtriCure closed the previous trading session at 19.08 up +0.76 4.12% with 19.790000915527344 shares trading hands.